Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects
JENDSO 6:1-7, Hamidi, S.,et al, 2022
Interim Results from the CATNON trial (EORTC study 260-53-22054) of treatment with Concurrent and Adjuvant Temozolomide for 1p/19q non-co-deleted anaplastic glioma: A phase 3, randomized, open-label intergroup study
Lancet 390:1645-1653, Van Den Bent, M.J.,et al, 2017
Safety and Diagnostic Value of Brain Biopsy in HIV patients: a Case Series and Meta-Analysis of 1209 Patients
JNNP 87:722-733, Lee, A.M.,et al, 2016
Randomized Phase III Study of Whole-Brain Radiotherapy for Primary CNS Lymphoma
Neurol 84:1242-1248, Korfel, A.,et al, 2015
Maintenance Therapy with Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma
JAMA 314:2535-2543,2511, Stupp, R.,et al, 2015
CT Angiography Findings in Carotid Blowout Syndrome and Its Role as a Predictor of 1-Year Survival
AJNR35:562-567, Lee, C-W.,et al, 2014
MATILDE Chemotherapy Regimen for Primary CNS Lymphoma
Neurol 82:1370-1373, Ferreri, A.J.M.,et al, 2014
Everolimus Long-Term Safety and Efficacy in Subependymal Giant Cell Astrocytoma
Neurol 80:574-580, Krueger, D.,et al, 2013
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
Antivenom for Critically Ill Children with Neurotoxicity from Scorpion Stings
NEJM 360:2090-2098, Boyer,L.V.,et al, 2009
High-Dose Cytarabine Plus High-Dose Methotrexate Versus High-Dose Methotrexate Alone in Patients with Primary CNS Lymphoma: A Randomised Phase 2 Trial
Lancet 374:1512-1520, 1477, Ferreri,A.,et al, 2009
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Long-Term Outcome in PCNSL Patients Treated with High-Dose Methotrexate and Deferred Radiation
Neurol 70:401-402, Gerstner,E.R.,et al, 2008
Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008